| Document |
Document Title |
|
WO/2024/064261A1 |
Embodiments of the present disclosure pertain to modified cells that include a fusion protein of NPC intracellular cholesterol transporter 2 protein (NPC2) and another protein. Additional embodiments of the present disclosure pertain to ...
|
|
WO/2024/060140A1 |
The present invention relates to a novel chimeric antigen receptor specifically binding to EGFRvIII and use thereof.
|
|
WO/2024/058178A1 |
The present invention provides a reagent that is for measuring an epidermal growth factor receptor tyrosine kinase activity and that contains: a modified polypeptide to which an acceptor and a donor inducing Förster resonance energy tra...
|
|
WO/2024/058155A1 |
The present invention addresses the problem of providing a new method for simply and efficiently producing linear covalently closed DNA. Provided is a double stranded circular DNA vector, wherein the double stranded circular DNA vector...
|
|
WO/2024/055457A1 |
Provided is the use of a JWA polypeptide in the preparation of an anti-Parkinson's disease drug. The amino acid sequence of the polypeptide is as shown in I or II: I: FPG SDRF-Z; II: X-FPGSDRF-Z, wherein amino acid S is subjected to phos...
|
|
WO/2024/059264A1 |
Described herein are compositions and methods for producing immune cells, such as regulatory T cells (Tregs), expressing a chimeric antigen receptor (CAR) which responds to a non-degradable engineered polymeric antigen in a site-specific...
|
|
WO/2024/056028A1 |
Provided are analgesic peptides. Also provided is a formulation comprising any one of the analgesic peptides and a pharmaceutically acceptable excipient. Also provided is a method for treating or preventing pain in a subject in need ther...
|
|
WO/2024/057094A2 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/055995A1 |
Provided are an anti-VEGFA fusion protein, and a preparation method therefor and the use thereof. The anti-VEGFA fusion protein has a high affinity with VEGFA, can effectively block the binding of VEGFA to receptor VEGFR, block a VEGFA s...
|
|
WO/2024/056098A1 |
Provided are an NK cell adapter molecule targeting an NKG2D ligand and an NKp46 and the use thereof. The cell adapter molecule at least comprises: a first binding domain comprising an NKG2D extracellular domain that can specifically bind...
|
|
WO/2024/053630A1 |
The present disclosure provides a new carrier peptide fragment having cell membrane permeability. The disclosed carrier peptide fragment comprises the following amino acid sequence: RKLAVYWSTYKRSR (SEQ ID NO: 1).
|
|
WO/2024/051751A1 |
Disclosed herein are anti-CD123 nanobodies, a chimeric antigen receptor, and use thereof. The nanobodies are VHH01 and VHH02. The nanobodies VHH01 and VHH02 both have good affinity and specificity for CD123. A chimeric antigen receptor a...
|
|
WO/2024/055002A1 |
Provided are a fusion protein comprising a mutated kinetochore protein and dCas9. The fusion protein is used in conjunction with guide RNAs target the fusion protein to a location of kinetochore assembly on a centromere such that the fus...
|
|
WO/2024/051802A1 |
Provided are a GIPR antibody, a fusion protein thereof with FGF21, a pharmaceutical composition thereof, and use thereof. Further provided is a method of the GIPR antibody and the fusion protein thereof with FGF21 for treating, preventin...
|
|
WO/2024/051817A1 |
The present invention relates to a tumor-targeted fusion protein type medicament precursor taking interleukin 2 as an active ingredient.
|
|
WO/2024/053550A1 |
The present invention addresses the problem of providing a method for, when a plurality of DNAs encoding the same or similar proteins are present, modifying the plurality of DNAs using TALE. More specifically, the present invention relat...
|
|
WO/2024/054991A1 |
A non-naturally occurring protein dimer is provided and comprises two monomers that are each antagonists of the Na/K-ATPase-Src receptor complex. Each peptide monomer has an amino acid sequence of SEQ ID NO: 1 or a functional fragment or...
|
|
WO/2024/051641A1 |
The present invention provides an anti-EGFR and cMet bispecific chimeric antigen receptor and use thereof. Specifically, the present invention provides an immune cell expressing a first CAR and a second CAR, the first CAR targets a first...
|
|
WO/2024/050627A1 |
Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides ...
|
|
WO/2024/050648A1 |
Methods of treating a subject who has or is at risk of having a chemo-resistant tumor comprising a step of administering a pharmaceutical composition comprising a self-assembled polypeptide complex, which methods result in slowing, inhib...
|
|
WO/2024/054897A1 |
The inventors hypothesized that the induction of a multitude of neoantigens in tumor cells, through hundreds of thousands of RNA editing events, would render tumors more recognizable by the patient's own T cells and that this could serve...
|
|
WO/2024/051831A1 |
The present invention relates to a constitutive chimeric cytokine receptor, comprising an extracellular domain and a constitutively activated IL-7R mutant. The extracellular domain consists of an effector molecule capable of remodeling t...
|
|
WO/2024/046239A1 |
The present invention relates to a specific recombinant humanized monoclonal antibody targeting human GPRC5D and an application thereof, can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeti...
|
|
WO/2024/046072A1 |
Disclosed are an immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof. Specifically, disclosed are mbIL-21 and a use thereof in immunotherapy. mbIL-21 can enhance the expansion capability...
|
|
WO/2024/046234A1 |
The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide, an expression vector, and a host cell that encode the antibody o...
|
|
WO/2024/049153A1 |
The present invention relates to a nanoparticle and a preparation method therefor, the nanoparticle comprising an amphiphilic peptide, which forms a micelle structure through self-assembly, and a target peptide (preferably, a water-solub...
|
|
WO/2024/048599A1 |
Provided is a highly stable and versatile protein-nucleic acid complex. This protein-nucleic acid complex comprises a nucleic acid molecule having uracil, a uracil DNA glycosylase domain covalently bound to the nucleic acid molecule, and...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/046394A1 |
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an im...
|
|
WO/2024/048050A1 |
According to the present disclosure, provided is a carrier peptide fragment having excellent cell membrane permeability. The disclosed carrier peptide fragment comprises an amino acid sequence represented by SEQ ID NO: 1, KKRTLRKSNRKKR, ...
|
|
WO/2024/045430A1 |
The present invention relates to the technical field of biological functions of proteins, and specifically relates to a polypeptide, a fused polymer protein and the use thereof. The polypeptide is selected from: (1) a polypeptide that ha...
|
|
WO/2024/048570A1 |
The present invention addresses the problem of providing a vaccine composition for nasal administration that is usable for preventing and treating hepatitis B, and a nasal administration system of the vaccine. Provided is a hepatitis B...
|
|
WO/2024/046404A1 |
A recombinant botulinum toxin and a preparation method therefor. By designing and optimizing the heavy chain and light chain sequences of the recombinant botulinum toxin, adding and cleaving protein tags will not introduce amino acid res...
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/047162A1 |
The present invention relates in general to the field of medicine. More particularly, it relates to polypeptide conjugates, compositions and methods for promoting immune tolerance to the CRISPR-Cas (Clustered Regularly Interspaced Short ...
|
|
WO/2024/046301A1 |
The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases.
|
|
WO/2024/041618A1 |
The present invention relates to an engineered immune cell co-expressing CD40L. In particular, the engineered immune cell of the present invention is a T cell or an NK cell. According to the present invention, a CAR molecule containing t...
|
|
WO/2024/044547A1 |
Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglob...
|
|
WO/2024/040681A1 |
The present invention relates to an uPAR-targeted third-generation chimeric antigen receptor, immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptor of the present invention, and a use of the ...
|
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
|
WO/2024/041477A1 |
Provided is use of a multi-domain fusion protein in the preparation of a medicament for treating or preventing tumors. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, a VEGF-antagonizing fragment and a TGF-β ...
|
|
WO/2024/044721A1 |
Embodiments of the present disclosure provide compositions and methods for injectable recombinant protein-based hydrogels for therapeutic delivery. Embodiments of the composition and methods comprise a recombinant protein, a cell consort...
|
|
WO/2024/044557A1 |
The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypep...
|
|
WO/2024/044574A1 |
The present disclosure provides methods for reducing ionizing radiation-induced damage of cells such as hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The methods comprise introducing into HSCs and/or HPCs a f...
|
|
WO/2024/044726A1 |
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protei...
|
|
WO/2024/044572A1 |
Modified DNA-binding proteins are provided. DNA binding proteins of interest include fusion proteins having a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence i...
|
|
WO/2024/041579A1 |
Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.
|
|
WO/2024/037531A1 |
Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, ...
|
|
WO/2024/039683A1 |
Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective u...
|
|
WO/2024/037322A1 |
Disclosed in the present invention are an IL-15 mutant-Fc/IL-15Rα subunit-Fc heterodimer and the use thereof. The heterodimeric protein comprises protein a and protein b, wherein the protein a comprises an IL-15 mutant and a first Fc mu...
|
